natgillin/translations-raw huggingface dataset:
Prader-Willi syndrome, for improvement of growth and body composition in paediatric patients Generally a dose of 0.035 mg/kg body weight per day or 1.0 mg/m2 body surface area per day is recommended.
Prader-Willijev sindrom (PWS), za izboljšanje rasti in sestave telesa pri pediatričnih bolnikih Običajen priporočen odmerek je 0,035 mg/kg telesne mase na dan ali 1,0 mg/m2 telesne površine na dan.
Pradofloxacin 25 mg/ml Preservative: Sorbic acid (E200)
Pradofloksacin 25 mg/ml Konzervans: sorbinska kislina (E200)
Pradofloxacin dose
Pradofloksacin
Pradofloxacin dose (mg/kg bw)
Pradofloksacin Odmerek (mg/kg t.m.)
Pradofloxacin has been shown to have no effects on fertility in breeding animals.
Pradofloksacin ne vpliva na plodnost pri vzrejnih živalih.
Pradofloxacin induced eye malformations at foetal and maternal toxic dosages in rats.
Pradofloksacin povzroča očesne okvare pri podganah pri odmerkih, ki imajo fetotoksični učinek ter toksični učinek na mater.
Praluent 150 mg solution for injection in a pre-filled pen alirocumab
Praluent 150 mg raztopina za injiciranje v napolnjenem injekcijskem peresniku alirokumab
Praluent 150 mg solution for injection in a pre-filled syringe alirocumab
Praluent 150 mg raztopina za injiciranje v napolnjeni injekcijski brizgi alirokumab
Praluent 150 mg solution for injection in pre-filled pen alirocumab
Praluent 150 mg raztopina za injiciranje v napolnjenem injekcijskem peresniku alirokumab
Praluent 150 mg solution for injection in pre-filled syringe alirocumab
Praluent 150 mg raztopina za injiciranje v napolnjeni injekcijski brizgi alirokumab
Praluent 75 mg injection alirocumab Subcutaneous use
Praluent 75 mg injekcija alirokumab subkutana uporaba
Praluent 75 mg solution for injection in a pre-filled pen alirocumab
Praluent 75 mg raztopina za injiciranje v napolnjenem injekcijskem peresniku alirokumab
Praluent 75 mg solution for injection in a pre-filled pen Praluent 150 mg solution for injection in a pre-filled pen
Praluent 75 mg raztopina za injiciranje v napolnjenem injekcijskem peresniku Praluent 150 mg raztopina za injiciranje v napolnjenem injekcijskem peresniku
Praluent 75 mg solution for injection in a pre-filled syringe alirocumab
Praluent 75 mg raztopina za injiciranje v napolnjeni injekcijski brizgi alirokumab
Praluent 75 mg solution for injection in a pre-filled syringe Praluent 150 mg solution for injection in a pre-filled syringe
Praluent 75 mg raztopina za injiciranje v napolnjeni injekcijski brizgi Praluent 150 mg raztopina za injiciranje v napolnjeni injekcijski brizgi
Praluent 75 mg solution for injection in pre-filled pen alirocumab
Praluent 75 mg raztopina za injiciranje v napolnjenem injekcijskem peresniku alirokumab
Praluent 75 mg solution for injection in pre-filled syringe alirocumab
Praluent 75 mg raztopina za injiciranje v napolnjeni injekcijski brizgi alirokumab
Praluent contains the active substance alirocumab.
Zdravilo Praluent vsebuje zdravilno učinkovino alirokumab.
Praluent has been studied in 10 main studies involving over 5,000 adult patients with hypercholesterolaemia (including patients with heterozygous familial disease) and mixed dyslipidaemia.
Zdravilo Praluent so proučevali v 10 glavnih študijah, v katerih je sodelovalo več kot 5 000 odraslih bolnikov s hiperholesterolemijo (vključno z bolniki s heterozigotno družinsko boleznijo) in mešano dislipidemijo.
Praluent is a clear, colourless to pale yellow solution for injection that comes in a pre-filled syringe.
Zdravilo Praluent je bistra, brezbarvna do bledo rumena raztopina za injiciranje v napolnjeni injekcijski brizgi.
Praluent is a medicine used to treat adults with primary hypercholesterolaemia (high blood cholesterol levels, in particular of the type ‘LDL-cholesterol’ or ‘bad’ cholesterol).
Praluent je zdravilo, ki se uporablja za zdravljenje odraslih s primarno hiperholesterolemijo (visokimi ravnmi holesterola v krvi, predvsem „holesterola LDL“ ali „slabega“ holesterola).
Praluent is a monoclonal antibody (a type of specialised protein designed to attach to a target substance in the body).
Zdravilo Praluent je monoklonsko protitelo (tip specializirane beljakovine, namenjene temu, da se veže na ciljno spojino v telesu).
Praluent is a monoclonal antibody (a type of specialised protein designed to attach to a target substance in the body).
Zdravilo Praluent je monoklonsko protitelo (tip specializirane beljakovine, namenjene temu, da se veže na ciljno spojino v telesu.).
Praluent is also used to treat mixed dyslipidaemia (abnormal levels of fats in blood, including high levels of LDL-cholesterol).
Zdravilo Praluent se uporablja tudi za zdravljenje mešane dislipidemije (nenormalnih ravni maščob v krvi, vključno z visokimi ravnmi holesterola LDL).
Praluent is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet: in combination with a statin or statin with other lipid lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin or, alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.
Zdravilo Praluent je indicirano pri odraslih bolnikih s primarno hiperholesterolemijo (heterozigotno familiarno ali nefamiliarno) ali mešano dislipidemijo kot dodatek dieti: v kombinaciji s statinom ali s statinom skupaj z drugimi hipolipemiki pri bolnikih, ki ciljnega holesterola LDL (LDL-H) ne morejo doseči z največjim toleriranim odmerkom statina, ali samo ali v kombinaciji z drugimi hipolipemiki pri bolnikih, ki statinov ne prenesejo ali so ti pri njih kontraindicirani.
Praluent is to be used together with a low-fat diet, in the following ways:
Zdravilo Praluent se skupaj z dieto z malo maščobami uporablja na naslednje načine:
Pramipexole Accord 0.088 mg tablet
Nenaden nepremagljiv spanec in zaspanost
Pramipexole Accord 0.088 mg tablets Pramipexole
Pramipeksol Accord 0,35mg tablete so pakirane v pretisnih omotih iz aluminija/aluminija.
Pramipexole Accord 0.18 mg tablet
Manija in delirij
Pramipexole Accord 0.35 mg
0,54 mg pramipeksola (0,75 mg soli).
Pramipexole Accord 0.35 mg tablet
Oftalmološki pregledi
Pramipexole Accord 0.7 mg tablets Pramipexole
Pramipeksol Accord 0,088 mg tablete Pramipeksol
Pramipexole Accord 1.1 mg
Pramipeksol Accord 0,18 mg
Pramipexole Accord 1.1 mg tablets Pramipexole
Pramipeksol Accord 0,18 mg tablete Pramipeksol
Pramipexole Accord 1.1 mg tablets Pramipexole
Pramipeksol Accord 0,35 mg tablete Pramipeksol
Pramipexole Accord can be used either on its own or in combination with levodopa (another medicine for Parkinson’s disease), at any stage of disease including the later stages when levodopa starts becoming less effective.
Zdravilo Pramipexole Accord se lahko uporablja samostojno ali v kombinaciji z levodopo (drugim zdravilom za zdravljenje Parkinsonove bolezni) v katerem koli stadiju bolezni, tudi v poznem stadiju, ko začne učinek levodope popuščati.
Pramipexole Accord is a ‘generic medicine’.
Zdravilo Pramipexole Accord je „generično zdravilo“.
Pramipexole Accord is used to treat the symptoms of Parkinson’s disease, a progressive brain disorder that causes shaking, slow movement and muscle stiffness.
Zdravilo Pramipexole Accord se uporablja za zdravljenje simptomov Parkinsonove bolezni, napredujoče okvare možganov, ki povzroča tresenje, upočasnjeno izvajanje gibov in otrplost mišic.
Pramipexole Accord tablets are packed in alu-alu blisters.
Pramipeksol Accord 0,18 mg tablete so pakirane v pretisnih omotih iz aluminija/aluminija.
Pramipexole alleviates Parkinsonian motor deficits by stimulation of dopamine receptors in the striatum.
Pramipeksol spodbuja dopaminske receptorje v striatumu in s tem blaži motorične motnje pri Parkinsonovi bolezni.
Pramipexole doses as published in the literature refer to the salt form.
Odmerki pramipeksola, objavljeni v literaturi, se nanašajo na sol.
Pramipexole has been associated with somnolence and episodes of sudden sleep onset, particularly in patients with Parkinson’s disease.
Pramipeksol je bil povezan z zaspanostjo in epizodami nenadnega spanca, zlasti pri bolnikih s Parkinsonovo boleznijo.
Pramipexole has been associated with somnolence and episodes of sudden sleep onset, particularly in patients with Parkinson’s disease.
Pramipeksol povezujejo z zaspanostjo in nenadnimi epizodami spanja, zlasti pri bolnikih s Parkinsonovo boleznijo.
Pramipexole is a dopamine agonist that binds with high selectivity and specificity to the D2 subfamily of dopamine receptors of which it has a preferential affinity to D3 receptors, and has full intrinsic activity.
Pramipeksol je dopaminski agonist s polno intrinzično aktivnostjo, katerega vezava na podskupino dopaminskih receptorjev D2, med katerimi ima preferenčno afiniteto za receptorje D3, je visoko selektivna in specifična.
Pramipexole is associated with somnolence (8.6%) and has been associated uncommonly with excessive daytime somnolence and sudden sleep onset episodes (0.1%). (See also section 4.4).
Zdravljenje s pramipeksolom povezujejo z zaspanostjo (8,6 %), občasno tudi s preveliko zaspanostjo čez dan, in z epizodami nenadnega spanca (0,1 %) (glejte tudi poglavje 4.4).
Pramipexole is bound to plasma proteins to a very low (< 20%) extent, and little biotransformation is seen in man.
Na plazemske beljakovine se veže zelo malo pramipeksola (< 20 %) in pri človeku je opažena le manjša biotransformacija.
Pramipexole is completely absorbed following oral administration.
Pramipeksol se po peroralnem jemanju hitro in popolnoma absorbira.
Pramipexole is metabolised in man only to a small extent.
Pramipeksol se pri ljudeh presnavlja le v manjši meri.
Pramipexole is rapidly and completely absorbed following oral administration.
Pramipeksol se po peroralnem jemanju hitro in v celoti absorbira.
Pramipexole may be associated with libido disorders (increased or decreased).
Pramipeksol lahko povzroči motnje libida (povečanje pri 0,1 % bolnikov ali zmanjšanje pri 0,4 % bolnikov).
Pramipexole prolonged-release tablets were non-inferior to pramipexole immediate release tablets as assessed on the UPDRS Parts II+III score at week 33.
Pramipeksol tablete s podaljšanim sproščanjem so bile enakovredne tabletam pramipeksola s takojšnjim sproščanjem, kar je pokazala ocena po lestvici UPDRS, II. in III. del, po 33 tednih.
Pramipexole should be tapered off at a rate of 0.54 mg of base (0.75 mg of salt) per day until the daily dose has been reduced to 0.54 mg of base (0.75 mg of salt).
Zdravljenje s pramipeksolom moramo ukinjati postopoma, in sicer po 0,54 mg (0,75 mg soli) na dan, dokler dnevnega odmerka ne zmanjšamo na 0,54 mg pramipeksola (0,75 mg soli).
Pramipexole shows linear kinetics and a small inter-patient variation of plasma levels.
Pramipeksol kaže linearno kinetiko in majhna odstopanja vrednosti plazemskih koncentracij med bolniki.
Pramipexole stimulates the brain as dopamine would, so that patients can control their movement and have fewer of the signs and symptoms of Parkinson’s disease, such as shaking, stiffness and slowness of movement.
Pramipeksol stimulira možgane enako kot dopamin, tako da lahko bolniki spet nadzirajo svoje gibe in kažejo manj znakov in simptomov Parkinsonove bolezni, kot so tresenje, okorelost in upočasnjeno izvajanje gibov.
Pramipexole stimulates the brain as dopamine would, so that patients can control their movement and have fewer of the signs and symptoms of Parkinson’s disease, such as shaking, stiffness and slowness of movement.
Pramipeksol stimulira možgane enako kot dopamin, tako da lahko bolniki spet nadzirajo svoje gibe in kažejo manj znakov in simptomov Parkinsonove bolezni, kot so tresenje, otrplost mišic in upočasnjeno izvajanje gibov.
Pramipexole Teva 0.088 mg tablets are white, round tablets, embossed with "93" on one side and "P1" on the other side.
Zdravilo Pramipeksol Teva 0,088 mg tablete je v obliki belih, okroglih tablet z izbočeno oznako »93« na eni strani in »P1« na drugi strani.
Pramipexole Teva 0.18 mg tablets are white round, scored tablets embossed with "P2" over "P2" on the scored side and "93" on the other side.
Zdravilo Pramipeksol Teva 0,18 mg tablete je v obliki belih, okroglih tablet z zarezo, z izbočeno oznako »P2«/«P2« na strani z zarezo in »93« na drugi strani.
Pramipexole Teva 0.35 mg tablets are white, oval, biconvex tablets, engraved with 9 vertical scoreline 3 on the scored side, and 8023 on the other side.
Zdravilo Pramipeksol Teva 0,35 mg tablete je v obliki belih ali skoraj belih, ovalnih, bikonveksnih tablet z vgraviranim 9 vertikalna črta 3 na eni strani in 8023 na drugi strani.
Pramipexole Teva 0.7 mg tablets are white, round, scored tablets embossed with "8024" over "8024" on the scored side and "93" on the other side.
Zdravilo Pramipeksol Teva 0,7 mg tablete je v obliki belih, okroglih tablet z zarezo, z izbočeno oznako »8024«/«8024« na strani z zarezo in »93« na drugi strani.
Pramipexole Teva can be taken with or without food.
Zdravilo Pramipeksol Teva lahko jemljete skupaj s hrano ali brez nje.
Pramipexole Teva can be used either on its own or in combination with levodopa (another medicine for Parkinson’s disease), at any stage of disease including the later stages when levodopa starts becoming less effective.
Zdravilo Pramipexole Teva se lahko uporablja bodisi samostojno bodisi v kombinaciji z levodopo (drugim zdravilom za zdravljenje Parkinsonove bolezni) v katerem koli stadiju bolezni, vključno s poznim stadijem, ko začne učinek levodope popuščati.
Pramipexole Teva can cause hallucinations (seeing, hearing or feeling things that are not there).
Zdravilo Pramipeksol Teva lahko povzroči halucinacije (pojav, pri katerem vidite, slišite ali čutite nekaj, česar ni).
Pramipexole Teva can have a major influence on the ability to drive and use machines.
Zdravilo Pramipeksol Teva ima pomemben vpliv na sposobnost vožnje in upravljanja s stroji.
Pramipexole Teva has been associated with sleepiness and episodes of suddenly falling asleep, particularly in patients with Parkinson’s disease.
Zdravilo Pramipeksol Teva so zlasti pri bolnikih s Parkinsonovo boleznijo povezovali z zaspanostjo in epizodami nepremagljivega spanca.
Pramipexole Teva is a ‘generic medicine’.
Pramipexole Teva je „generično zdravilo“.
Pramipexole Teva is indicated in adults for treatment of the signs and symptoms of idiopathic Parkinson’s disease, alone (without levodopa) or in combination with levodopa, i.e. over the course of the disease, through to late stages when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end of dose or “on off” fluctuations).
Zdravilo Pramipeksol Teva je pri odraslih indicirano za zdravljenje znakov in simptomov idiopatske Parkinsonove bolezni, same (brez levodope) ali v kombinaciji z levodopo, to je v napredovanem in poznem stadiju bolezni, ko prične z napredovanjem bolezni učinek levodope popuščati, postane nestalen in se pojavljajo fluktuacije terapevtskega učinka (konec odmerka ali vklopno-izklopni pojavi).
Pramipexole Teva is not recommended for use in children or adolescents under 18 years.
Uporabe zdravila Pramipeksol Teva pri otrocih in mladostnikih, mlajših od 18 let, ne priporočamo.
Pramipexole Teva is used to treat the symptoms of Parkinson’s disease, a progressive brain disorder that causes shaking, slow movement and muscle stiffness.
Zdravilo Pramipexole Teva se uporablja za zdravljenje simptomov Parkinsonove bolezni, napredujoče okvare možganov, ki povzroča tresenje, upočasnjeno izvajanje gibov in otrplost mišic.
Pramipexole Teva is used to treat the symptoms of primary Parkinson’s disease in adults.
Zdravilo Pramipeksol Teva uporabljamo za zdravljenje simptomov primarne Parkinsonove bolezni pri odraslih.
Pramipexole Teva should not be used during breast-feeding.
Če dojite, zdravila Pramipeksol Teva ne smete jemati.
Pramipexole Teva tablets are available in blister packs of 30, 30 x 1, 50 x 1, 100 x 1 and 100 tablets and bottles containing 90 tablets.
Zdravilo Pramipeksol Teva je na voljo v pretisnih omotih po 30, 30 x 1, 50 x 1, 100 x 1 in 100 tablet ter stekleničkah po 90 tablet.
Pramipexole Teva with food, drink and alcohol
Zdravila Pramipeksol Teva skupaj s hrano, pijačo in alkoholom
Pramipexole was not teratogenic in rats and rabbits, but was embryotoxic in the rat at maternotoxic doses (see section 5.3).
Pri podganah in zajcih ni bil teratogen, pri podganah je bil embriotoksičen v odmerkih, toksičnih za samico (glejte poglavje 5.3).
Prandial Blood-glucose Increment 90 minutes after dosing meal (Plasma) (mmol/l)
Prandialni porast glukoze v krvi 90 minut po obroku z aplikacijo zdravila (plazma) (mmol/l)
Prandin may not be suitable for you.
Zdravljenje z zdravilom Prandin pri vas morda ni primerno.
Prandin tablets are round and convex and engraved with the Novo Nordisk logo (Apis bull).
Tablete Prandin so okrogle in izbočene ter imajo vrezan logo družbe Novo Nordisk (bik Apis).
Prasugrel 5 mg provided greater antiplatelet effect than clopidogrel 75 mg.
Prasugrel 5 mg je omogočil večji antitrombotični učinek kot klopidogrel 75 mg.
Prasugrel At time of PCIa
Prasugrel v času perkutane koronarne intervencijea
Prasugrel should be used with caution in patients with a body weight of < 60 kg due to the potential risk of bleeding in this population (see section 4.4).
Prasugrel moramo uporabljati previdno pri bolnikih s telesno maso < 60 kg, zaradi možnega tveganja za krvavitev v tej populaciji (glejte poglavje 4.4).
Prasugrel should be used with caution in patients ≥ 75 years old and in patients weighing <60 kg (see sections 4.2, 4.4 and 4.8).
Prasugrel je treba uporabljati previdno pri bolnikih ≥ 75 let in pri bolnikih, ki tehtajo < 60 kg (glejte poglavja 4.2, 4.4 in 4.8).
Prasugrel-mediated inhibition of platelet aggregation exhibits low between-subject (9%) and within-subject (12%) variability with both 5 µM and 20 µM ADP.
Zaviranje agregacije trombocitov, inducirano s prasugrelom, kaže majhno variabilnost med osebami (9 %) in pri osebah (12 %) pri obeh, 5 µM ADP in 20 µM ADP.
Prasugrel’s pharmacokinetics are similar in healthy subjects, patients with stable atherosclerosis, and patients undergoing percutaneous coronary intervention.
Farmakokinetika prasugrela je podobna pri zdravih osebah, bolnikih s stabilno aterosklerozo in bolnikih, ki imajo perkutano koronarno intervencijo.
Pravafenix 40 mg/160 mg hard capsules
Pravafenix 40 mg/160 mg trde kapsule
Pravafenix 40 mg/160 mg hard capsules pravastatin/fenofibrate
Pravafenix 40 mg/160 mg trde kapsule pravastatin/fenofibrat
Pravafenix contains fenofibrate and pravastatin, which have different modes of action and show additive effects in terms of reduction of serum lipid.
Zdravilo Pravafenix vsebuje fenofibrat in pravastatin, ki imata različen način delovanja in v smislu zniževanja serumskih lipidov izkazujeta aditivno delovanje.
Pravafenix contains lactose
Pomembne informacije o nekaterih sestavinah zdravila Pravafenix
Pravafenix is indicated as an adjunct to diet and other non-pharmacological treatment (e.g. exercise, weight reduction) for the treatment of mixed hyperlipidaemia in adult patients at high cardiovascular risk to reduce triglycerides and increase HDL-C when LDL-C levels are adequately controlled while on a treatment with pravastatin 40 mg monotherapy.
Zdravilo Pravafenix je indiciran za zdravljenje odraslih bolnikov z visokim tveganjem za koronarno bolezen srca in mešano dislipidemijo (za katero so značilne visoke vrednosti trigliceridov in nizke vrednosti holesterola HDL), pri katerih so vrednosti holesterola LDL ustrezno nadzirane z monoterapijo s 40 mg pravastatina.
Pravafenix is used if you are an adult with an elevated risk for heart disease and need to improve cholesterol and triglycerides fat levels in your blood when your ‘bad’ cholesterol levels are being adequately controlled with pravastatin alone (a statin, a cholesterol-lowering medicine).
Zdravilo Pravafenix ste dobili, če ste bolnik z zvišanim tveganjem za bolezni srca in morate izboljšati raven holesterola in trigliceridnih maščob v krvi in če je vaš „slabi“ holesterol ustrezno nadzorovan samo s pravastatinom (statinom, zdravilom za zniževanje ravni holesterola).
Pravafenix is used in adults at high risk of heart disease whose ‘low-density-lipoprotein’ (LDL or ‘bad’) cholesterol is already being controlled with pravastatin alone but who still need to improve their cholesterol levels and to reduce their levels of triglycerides (a type of fat).
Zdravilo Pravafenix se uporablja za zdravljenje odraslih bolnikov z visokim tveganjem za bolezen srca, pri katerih so vrednosti holesterola zaradi „lipoproteinov nizke gostote“ (holesterol LDL ali slabi holesterol) že nadzirane z monoterapijo s pravastatinom, vendar morajo kljub temu še izboljšati raven holesterola in zmanjšati raven trigliceridov (vrsta maščob).
Pravafenix should be discontinued if gallstones are found.
Če so odkriti žolčni kamni, je treba zdravljenje z zdravilom Pravafenix prekiniti.
Pravafenix with food, drink and alcohol
Zdravilo Pravafenix skupaj s hrano in pijačo
pravastatin
telaprevirjem
Pravastatin (40 mg single dose)/ velpatasvir (100 mg once daily)d
Pravastatin (40 mg enkratni odmerek)/velpatasvir (100 mg enkrat na dan)d
Pravastatin 10
pravastatin
pravastatin AUC ↑ 63%
pravastatin AUC ↑ 63
pravastatin AUC ↑ 81%¶ pravastatin Cmin ND pravastatin Cmax ↑ 63%
pravastatin Cmin ND pravastatin Cmax ↑ 63
Pravastatin belongs to the group called ‘statins’.
Pravastatin spada v skupino, imenovano „statini“.
pravastatin Cmax ↑ 49%
pravastatin Cmax ↑ 49
pravastatin Cmax ↑ 63%
pravastatin Cmin ND pravastatin Cmax ↑ 63
Pravastatin Fluvastatin (saquinavir/ritonavir)
kupaj z zdravilom
Pravastatin Fluvastatin (saquinavir/ritonavir)
pravastatin fluvastatin (sakvinavir/ritonavir)
Pravastatin is administered orally in the active form.
Pravastatin se jemlje peroralno v aktivni obliki.
pravastatin, rosuvastatin: medicines to lower elevated cholesterol levels.
pravastatin, rosuvastatin: zdravila za zniževanje zvišanih ravni holesterola
Pravastatin, used to reduce cholesterol levels.
pravastatin, ki se uporablja za zmanjšanje ravni holesterola,
pravastatin.
pravastatinu.
Pravastatin/Efavirenz (40 mg once daily/600 mg once daily)
pravastatin/efavirenz (40 mg enkrat na dan/600 mg enkrat na dan)
Pravastatin/Efavirenz (40 mg q.d./600 mg q.d.)
atorvastatin/dizoproksiltenofovirijev fumarat pravastatin/efavirenz (40 mg dnevno/600 mg dnevno)
pravastatine and rosuvastatine, medicines used to reduce cholesterol levels. sulfasalazine, a medicine used to treat inflammatory bowel disease or rheumatoid arthritis.
pravastatin in rosuvastatin, zdravili za zniževanje ravni holesterola, sulfasalazin, zdravilo za zdravljenje vnetne bolezni črevesa in revmatoidnega artritisa.
Praxbind (2x2.5 g/50 mL) is administered intravenously, as two consecutive infusions over 5 to 10 minutes each or as a bolus injection.
Zdravilo Praxbind (2 x 2,5 g/50 ml) dajemo intravensko v dveh zaporednih infuzijah, ki vsaka traja 5 do 10 minut, ali kot bolusno injekcijo.
Praxbind 2.5 g/50 mL solution for injection/infusion
Praxbind 2,5 g/50 ml raztopina za injiciranje/infundiranje
Praxbind 2.5 g/50 mL solution for injection/infusion Idarucizumab
Praxbind 2,5 g/50 ml raztopina za injiciranje/infundiranje idarucizumab
Praxbind contains the active substance idarucizumab.
Vsebuje zdravilno učinkovino idarucizumab.
Praxbind contains the active substance idarucizumab.
Zdravilo Praxbind vsebuje zdravilno učinkovino idarucizumab.
Praxbind has not been studied in patients with hepatic impairment.
Zdravila Praxbind niso proučevali pri bolnikih z jetrno okvaro.
Praxbind is used in adults in emergency situations where your doctor decides that rapid inactivation of the effect of Pradaxa is required
Zdravilo Praxbind uporabljamo pri odraslih v nujnih primerih, v katerih zdravnik odloči, ali je potrebno hitro izničenje učinka zdravila Pradaxa:
Praxbind treatment can be used in conjunction with standard supportive measures, which should be considered as medically appropriate.
Zdravljenje z zdravilom Praxbind lahko izvajamo sočasno z drugimi standardnimi podpornimi ukrepi, ki jih je treba izvajati zdravstveno ustrezno.
prayer (glass)
nosnik (steklo)
Praziquantel (mg) (mg/kg bw)
Prazikvantel (mg) (mg/kg t.m.)